Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

NCT00614042 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Non-Hodgkin's Lymphoma (NHL)

Interventions

DRUG: TRU-016 (anti-CD37 protein therapeutic)

Sponsor

Aptevo Therapeutics